NASDAQ: BIDU

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

RD Technologies expands Ghana-Asia payment push with RDUSD as it shifts towards stablecoin settlement

Florida jet crash kills nine as Learjet 60 plunges near homes in Palm Beach County

Westpac reports A$6.8bn profit as bad debt charges double and lending margins tighten

McCain Foods expands India manufacturing footprint with Falcon Agrifriz acquisition as frozen potato demand grows

Baidu (NASDAQ: BIDU) proposes Kunlunxin spin-off in Hong Kong to unlock AI chip value

Baidu plans to spin off Kunlunxin via a Hong Kong listing to unlock chip value and streamline its AI portfolio. Will the market bite? Read the full story.

bySrinath

January 3, 2026

FSD in China by 2026? Tesla’s bet comes as EV rivals gain ground fast

Tesla expects full FSD approval in China by early 2026. Can this software milestone help reclaim market share from XPeng and Baidu?

byPallavi Madhiraju

November 11, 2025

The Latest

RD Technologies expands Ghana-Asia payment push with RDUSD as it shifts towards stablecoin settlement

Florida jet crash kills nine as Learjet 60 plunges near homes in Palm Beach County

Westpac reports A$6.8bn profit as bad debt charges double and lending margins tighten

McCain Foods expands India manufacturing footprint with Falcon Agrifriz acquisition as frozen potato demand grows

Baidu (NASDAQ: BIDU) proposes Kunlunxin spin-off in Hong Kong to unlock AI chip value

FSD in China by 2026? Tesla’s bet comes as EV rivals gain ground fast

RD Technologies expands Ghana-Asia payment push with RDUSD as it shifts towards stablecoin settlement

Florida jet crash kills nine as Learjet 60 plunges near homes in Palm Beach County

Westpac reports A$6.8bn profit as bad debt charges double and lending margins tighten

McCain Foods expands India manufacturing footprint with Falcon Agrifriz acquisition as frozen potato demand grows

Is water becoming the next infrastructure bottleneck for AI and chip factories?

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?